| Drug Name | Sovaldi® (Sofosbuvir) and Harvoni® (Ledipasvir) |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Infectious disease
|
| Risk |
Serious cases of symptomatic bradycardiaas well as one case fatal cardiac arrest reported with Co-administration of Amiodarone with either Harvoni® or with Sovaldi® in combination with Another Direct Acting Antiviral |
| Dear Healthcare provider letter DHPC |
|